Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University of Manitoba
Case Comprehensive Cancer Center
University of Turin, Italy
Stanford University
Ohio State University Comprehensive Cancer Center
Hackensack Meridian Health
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
City of Hope Medical Center
Massachusetts General Hospital
Assistance Publique - Hôpitaux de Paris
University of Washington
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
Massachusetts General Hospital
Azienda Ospedaliero-Universitaria di Parma
Azienda Ospedaliero-Universitaria di Parma
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Mayo Clinic
University of Miami
Dartmouth-Hitchcock Medical Center
Children's Hospital Medical Center, Cincinnati
Azienda Ospedaliero-Universitaria di Parma
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Azienda Ospedaliero-Universitaria di Parma
M.D. Anderson Cancer Center
Hannover Medical School
Washington University School of Medicine
City of Hope Medical Center
Dana-Farber Cancer Institute
MPN Research Foundation
Fred Hutchinson Cancer Center
Brigham and Women's Hospital
University Hospital, Bordeaux
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota